Navigation Links
Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
Date:9/18/2008

HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands, Sept. 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare Improvement CBO. The CBO guidelines, which cover all areas of healthcare and have an important role to play in the improvement of the quality of patient treatment and care, were drafted in collaboration with the Dutch Association of Comprehensive Cancer Centers (ACCC) and the Dutch National Breast Cancer Consultation Group (NABON).

The inclusion of MammaPrint in CBO's updated clinical practice guidelines represents a significant step forward for the role of molecular diagnostics in breast cancer treatment planning. Specifically, the new guidelines acknowledge the prognostic power of MammaPrint in general and highlight its ability to identify subgroups of untreated node negative patients as having a good or poor prognosis. The test also allows physicians and patients to determine with which therapy, if any, to address each individual patient's risk profile, ultimately providing a significant benefit of more personalized medicine. The Dutch guideline committee also encouraged physicians to enter patients into the MINDACT trial to allow establishing additional knowledge.

"We are delighted that MammaPrint has been included in the CBO guidelines," said Bernhard Sixt, Ph.D., president and chief executive officer of Agendia. "With a very high accuracy, MammaPrint identifies patients who have a risk of developing metastases within five to seven years after surgery. Therefore, the test is a very powerful tool that allows physicians to assess the rationale of adjuvant chemotherapy, which has been shown to be effective in reducing these early events in a meta-analysis of studies that included 30,000 patients."

The Dutch Institute for Healthcare Improvement CBO was founded in 1979 by the Dutch Association of Medical Specialists and Dutch Association of Chief Medical Officers, as an independent, not-for-profit foundation devoted to improving the quality of patient care in The Netherlands. The guidelines are available online at http://www.cbo.nl and are published in the September/October issue of the Journal of the Dutch Association of Medical Oncology.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint(R) measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint(R) test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result serves to help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint(R) tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The company markets four products based on its breakthrough platform for tumor gene expression profiling, and has several new diagnostic tests under development. Agendia was the first company to receive FDA clearance for a breast cancer test, MammaPrint(R) that predicts the risk of breast cancer recurrence. In addition, the company collaborates with pharma companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information on Agendia, please visit http://www.agendia.com.

MEDIA CONTACTS:

U.S. Media Contact:

Kelly Connor

Vice President

Ogilvy Public Relations Worldwide

+1.212.880.5328 Office

+1.609.221.5785 Mobile

Kelly.connor@ogilvypr.com

EU and non-US Media:

Hans Herklots

Head of Corporate Communications

Agendia

+31.20.462.1557 Office

+31.620.083.509 Mobile

hans.herklots@agendia.com


'/>"/>
SOURCE Agendia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
2. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
3. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
4. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
5. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
6. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
7. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
8. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
10. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... Feb. 19, 2017   AC Group Inc. , ... ranking of vendors in the PMS/EHR healthcare marketplace, will ... system requirements to succeed in this ecosystem at HIMSS,17. ... together information obtained from over 200 ACOs, compared and ... and services companies that are providing different pieces of ...
(Date:2/19/2017)... , February 18, 2017 Marapharm ... to purchase a Medical Delivery Service with the specific ... transactions between qualified patients and caregivers. The delivery service ... located in the Coachella Valley, California ... Los Angeles area to the West, population ...
(Date:2/18/2017)... Feb. 17, 2017   Parker Waichman ... the rights of victims injured by medical devices, ... to call for better reporting. Congress required hospitals ... Safety concerns involving power morcellators and duodenoscopes prompted ... investigate how hospitals report injuries and deaths related ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and Related ... Chuck E. Cheese’s locations throughout New England, New York and New Jersey to provide ... the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain Department ... being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as a ... department in early 2016. After a nation-wide search, she was selected to head the ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... result in better care, and MEDfx and the Delaware Health Information Network (DHIN) ... , As the nation’s first state-wide health information exchange, DHIN stores and shares ...
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, ... Pet Life Radio network. The episode, which was posted this week, features a ... factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association of ...
Breaking Medicine News(10 mins):